NovoCure Q2 Revenue Jumps 16%, Adjusted EBITDA Turns Positive; Guidance Raised
NVCR sits 71% above its 52-week low of $9.82.
Summary
NovoCure reported Q2 2026 revenue of $183.6M (+16% YoY) and positive Adjusted EBITDA of $10.8M. Full-year guidance was raised on both top and bottom lines. The Optune Pax launch contributed 285 active patients.
Key Events · Earnings and Guidance · NVCR
-
Record Revenue and Patient Growth
Q2 net revenues reached $183.6M, up 16% year-over-year, driven by 18% growth in global active patients to 5,128. Optune Gio remains the core driver with 4,636 active patients.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA swung to $10.8M from a loss of $9.9M a year ago, reflecting operating leverage and lower R&D costs. Net loss narrowed to $15.7M from $40.1M.
-
Optune Pax Launch Gains Momentum
Optune Pax contributed $1.6M in revenue and reached 285 active patients in the U.S. following its CE Mark approval in June. The launch is a key growth catalyst.
-
Full-Year Guidance Raised
Management lifted 2026 revenue guidance to $710M-$725M (from $690M-$710M) and Adjusted EBITDA to $0M-$15M (from a loss of $15M to breakeven), signaling confidence in the commercial trajectory.
Analysis · NVCR · Industrial Applications And Services
NovoCure delivered its strongest quarter yet, with record revenue and a swing to positive Adjusted EBITDA. The Optune Pax launch is gaining traction, adding 285 active patients. Management raised full-year revenue and EBITDA guidance, signaling confidence in the commercial ramp. The balance sheet remains solid with $440.6M in cash, providing ample runway. This quarter marks a turning point toward profitability after the TRIDENT trial setback.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.9% of the 1728 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.06%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVCR was trading at $16.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.82 to $18.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.